SamanTree Medical

Executive Summary

SamanTree Medical is a Swiss medical device company pioneering real-time, high-resolution tissue imaging with its Histolog Scanner. The system uses proprietary confocal microscopy to visualize tissue microstructures at the cellular level directly on fresh, unsectioned specimens, preserving the tissue for subsequent pathology. This technology addresses a critical unmet need in surgical oncology by enabling intraoperative assessment of tumor margins, potentially reducing re-excision rates and improving patient outcomes. The company is focused on commercializing its platform across multiple surgical specialties, including breast cancer, skin cancer, and other solid tumors. Since its founding in 2017, SamanTree has positioned itself at the intersection of medical devices and digital pathology. The Histolog Scanner offers a significant advantage over traditional frozen section analysis by providing immediate, high-quality images without tissue destruction. While the company is still in the growth phase, its technology has attracted interest from leading surgical centers. Key upcoming milestones include expanding clinical evidence, securing regulatory approvals in key markets, and forging strategic partnerships to accelerate adoption. With a strong value proposition in precision surgery, SamanTree is well-placed to capture share in the intraoperative imaging market.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for Histolog Scanner55% success
• Q2 2026Publication of pivotal clinical study results in breast cancer70% success
• Q3 2026Strategic partnership with a major surgical robotics company40% success